Groups Representing 340B Hospitals Praise Federal Court Decision Halting Deep Medicare Part B Cuts

U.S. District Court for the District of Columbia building
The federal district court in Washington, D.C. has ordered the government to immediately begin to pay 340B hospitals at full rates for Medicare Part B covered drugs.

In a big victory for 340B hospitals, a federal judge in Washington, D.C. ruled yesterday that the government must immediately begin to pay 340B hospitals the full Medicare Part B drug payment rate for the remainder of calendar year (CY)

Read More »

Manchin and Braun Call on HHS To Take Immediate Action Against Drug Manufacturers in Contract Pharmacy Battle

Sen. Joseph Manchin (D-WV) and Sen. Michael Braun (R-IN) headshots
Senators Manchin (D-WV) and Braun (R-Ind.) are urging HHS to take action against drug manufacturers who have placed restrictions in the contract pharmacy setting.

Government health officials need to take immediate action to fully enforce the law against drug makers who are denying 340B drug discounts to providers who use contract pharmacies to dispense 340B-priced drugs, U.S. Senator Joe Manchin (D-W.VA.) and U.S. Senator

Read More »

CVS Moves to Dismiss New York AG’s Antitrust Suit That Alleges Monopolistic Behavior Related to Wellpartner

CVS pharmacy retail building
CVS has asked a New York state court to dismiss an antitrust lawsuit alleging that the chain is forcing the state’s 340B covered entities to use its 340B third party administrator Wellpartner.

CVS Health Corp. has asked a New York state court to dismiss the state’s antitrust lawsuit alleging that the pharmacy chain is forcing the state’s 340B covered entities to use its 340B third party administrator Wellpartner as a condition for

Read More »

Generic/OTC Drug Maker Owes Refunds to 340B Providers, HRSA Audit Shows

screenshot of HRSA FY 2022 manufacturer audit results page
HRSA released findings from its audit of drug company VistaPharm.

The U.S. Health Resources Services Administration (HRSA) has ordered South Carolina-based VistaPharm, a manufacturer of generic and over-the-counter (OTC) drugs to repay overcharges to 340B covered entities after a HRSA audit showed the company did not offer its products at the

Read More »

Breaking News

National Association of Community Health Centers Calls On Congress “To Move Urgently” To Tackle 340B Contract Pharmacy Impasse “Before It’s Too Late”

Screenshot of U.S. Dept. of Health and Human Services dispute resolutions document
After the government’s Administrative Dispute Resolution panel dismissed its complaint against drug manufacturers, NACHC is calling for Congress to take urgent action to address the contract pharmacy impasse.

Sparked by the dismissal of its complaint against Astra Zeneca and Sanofi by the government’s Administrative Dispute Resolution Panel (ADR), the National Association of Community Health Centers say “they cannot wait any longer for a solution,” to the two-year standoff

Read More »

340B HIV Providers Warn of “Drug Industry Disinformation Campaign”

Shannon Stephenson headshot
Drug manufacturers’ true goal is to cripple the 340B program, says Shannon Stephenson, RWC-340B President and CEO of Cempa Community Cares.

Ryan White Clinics for 340B Access (RWC-340B), a national organization of 340B HIV/AIDS medical providers, has published a detailed rebuttal of several recently published articles criticizing the 340B program.  RWC-340B accuses article authors—many of whom are supported by the drug

Read More »

PhRMA, BIO, and Others Unleash a Torrent of 340B Hospital Criticism

screenshot of PhRMA blog post September 15, 2022
Headline from recent blog post by PhRMA spokesperson Nicole Longo.

340B disproportionate share hospitals (DSH) in 2020 spent 2.2 times more on outpatient drugs per commercially insured patient than non-340B DSH hospitals and 2.6 times more than other types of 340B hospitals, a new drug industry-funded study shows.

The

Read More »

Walgreens Takes Full Ownership of 340B Specialty Pharmacy Company Shields Health Solutions

Screenshot of Business Wire announcement Walgreens Boots Alliance, Inc. to gain ownership of Shields Health Solutions
Walgreens Boots Alliance (WBA) announced September 20th that it is acquiring the remaining 30% stake in 340B specialty pharmacy company Shields Health Solutions that it did not already own.

Walgreens Boots Alliance (WBA) announced September 20th that it is acquiring the remaining 30% stake in 340B specialty pharmacy company Shields Health Solutions that it did not already own. WBA first invested in Shields in July 2019. Last year, it spent

Read More »

Merck Announces Third Round of 340B Refunds for 2019 Drug Purchases

Merck corporate campus signage
Merck has announced its third round this year of refunds to 340B covered entities for overcharges on select products.

Drug manufacturer Merck has announced its third round this year of refunds to 340B covered entities for overcharges on select products.

The latest round covers 15 NDCs sold during Q3 2019. The previously announced refunds were for sales during Q1

Read More »

Unichem Says 340B Audit Found it Overcharged Just Two Entities and Must Repay Them Just $110.20

Drug manufacturer Unichem wordmark on building
Generic drug manufacturer Unichem says a 340B compliance audit found it overcharged just two entities and the repayment to both totals just $110.20.

Late last month, the U.S. Health Resources and Services Administration (HRSA) said on its website that generic drug manufacturer Unichem Pharmaceuticals USA had to repay 340B covered entities for overcharges found during a 340B program compliance audit.

According to Unichem,

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live